Skip to content
FrontierPicks
Portfolio
Search

Watching

KRMN · Karman Holdings Inc.

Updated ·

Price against the kill line

15.6% above its kill line on the 10 November 2026 close.

How to read this

The red mark is the published kill line — the price that would prove the research note wrong. The dot is where the stock closed on 10 November 2026; a dot left of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale.

The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides

KRMNKarman Holdings Inc.
$38.00
$43.91
15.6%well clear

3 months to −29.1% from the close, against the S&P 500's −2.7% over the same sessions. Figures in the note can cover a different window.

Kill line

A daily close below $38, which would erase the full post-report gain of 6 November 2026 and return the shares to their late-October range. A further break would be fiscal 2026 revenue below the $755 million low end of guidance, or a 2027 outlook under 20% organic growth.

Research onlyNot in the portfolio.

The portfolio's record →

The thesis

Karman Space & Defense is growing much faster than its share price suggests. Third-quarter fiscal 2026 revenue rose 66% and backlog doubled to $1.7 billion. Yet the shares closed at $43.91 on 10 November 2026, 61.9% below their 52-week high of $115.29. The fourth-quarter report and first 2027 outlook, expected around March 2027, settle the case. That report shows whether revenue lands inside the raised $755 million to $760 million guidance, and whether 2027 keeps the 20% to 25% organic growth management cites.

Nothing company-specific has changed since the 10 November 2026 note. The shares closed at $45.90 on 9 November 2026 and $43.91 on 10 November 2026. They gave back part of the post-report gain but stayed above the $38 level that marks the invalidation of the case. The late-October picture adds context. MarketBeat reported that the shares opened at $35.34 on 22 October 2026, the day Oppenheimer started coverage with an outperform rating and a $40 target. MarketBeat put the 12-month low at $29.34.

The narrative is maturing. The missile-supplier story is well known, and the shares fell 27.4% over the three months to 10 November 2026 even though each recent quarter beat estimates. Attention after the 5 November 2026 report produced one strong session and analyst target changes, then faded. In this view, the gap between the business and the price reflects the valuation investors will pay after heavy selling by former owners. An operating shortfall does not explain it.

Bullish and bearish views on Karman Holdings Inc.

The bull case on Karman Holdings Inc. (KRMN), in brief: Backlog doubled in nine months. The bear case: Debt rose with the Walker deal.

Bull case

  • Backlog doubled in nine months. Backlog reached a record $1.7 billion at 30 September 2026, up 108% from fiscal year-end 2025. Third-quarter bookings were nearly $465 million (company 8-K, 5 November 2026). Backlog had been $1.3 billion at 30 June 2026 (8-K, 6 August 2026).
  • Guidance raised for a second quarter. On 5 November 2026 the company lifted fiscal 2026 revenue guidance to $755–760 million. It raised adjusted EBITDA guidance to $225–227 million. Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, excluding one-off items. In August the ranges were $730–745 million and $215.0–222.5 million. Benzinga put consensus revenue at $742.2 million.
  • Missile programs drive the growth. Third-quarter revenue rose 39.6% to $51.1 million in Hypersonics and Strategic Missile Defense. It rose 51.9% to $67.6 million in Tactical Missiles and Integrated Defense Systems (8-K, 5 November 2026). In October 2026 the company announced a seven-year, $218 million Lockheed Martin agreement to supply parts for THAAD (Terminal High Altitude Area Defense).
  • Organic growth is strong without deals. Organic growth was 25% in the third quarter (8-K, 5 November 2026). Benzinga reported adjusted earnings per share of $0.19 against a $0.15 estimate. It reported sales of $201.6 million against a $194.7 million estimate.
  • A director bought near the lows. Director David Stinnett bought 27,000 shares on 16 September 2026 at an average of $37.32, according to MarketBeat's summary of the filing. That price is below the 10 November 2026 close of $43.91.
  • Most targets sit above the close. Benzinga reported these targets: Barclays $80 (raised 9 November 2026), KeyBanc $65 (2 November 2026), Piper Sandler $60 (raised 6 November 2026), RBC $60 (28 October 2026) and Needham $50 (cut 6 November 2026). Oppenheimer's $40 target from 22 October 2026 is the one below the $43.91 close.

Bear case

  • Debt rose with the Walker deal. Long-term debt net of the current portion was $851.5 million at 30 September 2026, against $68.2 million of cash (8-K, 5 November 2026). The company paid $94.2 million net for Walker Precision in the quarter.
  • Cash conversion is thin. Third-quarter operating cash flow was $26.7 million and free cash flow $13.4 million, against $20.9 million of net income (8-K, 5 November 2026).
  • The space segment is shrinking. Space and Launch revenue fell 6.9% year over year to $37.9 million in the third quarter (8-K, 5 November 2026). A NASA JPL selection for the SkyFall Mars parachute system, reported by Yahoo Finance on 6 November 2026, has no disclosed value.
  • Margins slipped slightly. The third-quarter adjusted EBITDA margin was 30.0%, compared with 31.0% a year earlier (8-K, 5 November 2026).
  • Analyst targets have fallen since August. Needham cut from $125 to $80 on 7 August 2026 and to $50 on 6 November 2026. RBC cut from $85 to $70 on 28 September 2026 and to $60 on 28 October 2026, according to MarketBeat and Benzinga.
  • Former owners have sold heavily. Selling stockholders sold 14 million shares at $61 in a secondary offering of about $854 million priced on 28 May 2026, according to Panabee. The company received none of the proceeds. Lock-ups from July 2025 let more former-owner shares become saleable in 2027.

Price setup

The shares closed at $43.91 on 10 November 2026, according to adjusted daily closes. That is 61.9% below the 52-week high of $115.29, and the shares fell 27.4% over three months. The 14-day relative strength index (a 0–100 momentum gauge) was 62.7. That reading is firm but below the 70 level usually read as stretched.

The low point of the autumn decline was well under today's price. MarketBeat reported a 12-month low of $29.34 and an open of $35.34 on 22 October 2026. On that date MarketBeat put the 50-day moving average at $39.72 and the 200-day moving average at $52.72. The shares have recovered toward the old 50-day level but remain well under the 200-day average from that date. The close of $45.61 on 6 November 2026 came after an 11.8% jump on the results.

Signs of crowding are limited. Earnings are about four months away. No new share sale has been announced since the May 2026 secondary. The visible insider activity in the past quarter is the September director purchase.

Catalysts, next 30 days

  • No dated company event through 11 December 2026. The company has not announced an investor day, offering or report for the next 30 days. Analyst target changes and contract announcements are the likely news flow.
  • ~March 2027 (est.): fourth-quarter and full-year fiscal 2026 report. This report shows whether revenue lands inside the $755–760 million guidance. It also shows whether the first 2027 outlook holds the 20% to 25% organic range. The case turns on it.
  • 2027 (date not fixed): lock-up releases for former owners. Lock-ups agreed in July 2025 hold 75% of senior Trive Capital principals' shares for 720 days, according to Panabee. More shares can come to market in 2027.

What would change the view

The case breaks if the growth fails to show up in the fourth-quarter report. That means fiscal 2026 revenue below the $755 million low end of guidance, or a 2027 outlook under 20% organic growth. A second straight year-over-year decline in Space and Launch would weaken it. So would long-term debt rising above $851.5 million without higher EBITDA guidance. A new secondary offering by former owners before the report would add supply the current price has not had to absorb.

On price, a daily close below $38 would erase the full post-report gain. It would return the shares to the range they traded in during late October, which would show that the market has rejected the third-quarter results.

What it trades with

Karman trades with listed defense suppliers such as Cadre Holdings, StandardAero and Ultralife. The group has drawn renewed attention in November. A firm group helps the shares but does not make the case. If peers rise while Karman stays below its post-report close of $45.61 from 6 November 2026, the problem is specific to Karman, most likely its debt or holder supply.

Broad market swings matter too. The 11.8% jump on 6 November 2026 came on the day the Nasdaq 100 rebounded 2% after its worst day since 2020, according to Benzinga. With $851.5 million of long-term debt at 30 September 2026, the shares are also exposed to interest-rate moves. The Space and Launch segment adds some exposure to commercial space sentiment.

Notes

  • Karman Holdings trades on the NYSE as KRMN and operates under the name Karman Space & Defense.
  • The company's fiscal year matches the calendar year; fiscal third quarter 2026 ended 30 September 2026.
  • Company revenue and EBITDA guidance excludes future acquisitions, so deals such as Walker Precision can lift reported growth above organic growth.
  • Lock-ups agreed in July 2025 hold 75% of senior Trive Capital principals' shares for 720 days, so more former-owner shares can become saleable in 2027.
The evidence, claim by claim (8)
  1. Third-quarter fiscal 2026 revenue was $201.6 million, up 65.6% year over year, with 25% organic growth. Karman 8-K earnings release, Exhibit 99.1 · as of
  2. Backlog reached a record $1.7 billion, up 108% from fiscal year-end 2025; third-quarter bookings were nearly $465 million. Karman 8-K earnings release, Exhibit 99.1 · as of
  3. Fiscal 2026 guidance raised to $755–760 million revenue and $225–227 million adjusted EBITDA, from $730–745 million and $215.0–222.5 million. Karman 8-K earnings releases of 6 August 2026 and 5 November 2026 · as of
  4. Long-term debt net of current portion was $851.5 million and cash was $68.2 million; third-quarter free cash flow was $13.4 million. Karman 8-K earnings release, Exhibit 99.1 · as of
  5. Barclays kept an overweight rating and raised its target to $80; Piper Sandler raised to $60 and Needham cut to $50 on 6 November 2026. Benzinga analyst rating items, 6 November 2026 and 9 November 2026 · as of
  6. Oppenheimer initiated coverage with an outperform rating and a $40 target; the shares opened at $35.34 that day and the 12-month low was $29.34. MarketBeat, 22 October 2026 · as of
  7. Director David Stinnett bought 27,000 shares at an average price of $37.32. MarketBeat summary of insider filing, 22 October 2026 · as of
  8. Selling stockholders sold 14 million shares at $61 in a secondary offering of about $854 million; the company received no proceeds. Panabee report on the 28 May 2026 offering pricing · as of

Sources

Related · shared themes